ArticleThe International journal of angiology : official publication of the International College of Angiology, Inc2026
Cumulative Serum Endothelin-1 and Endothelin-3 Level Predicts 1-year Adverse Cardiac Events after ST-Elevation Acute Myocardial Infarction.
Article in The International journal of angiology : official publication of the International College of Angiology, Inc, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelin-1 (ET-1) and endothelin-3 (ET-3) released in circulation during acute myocardial infarction (AMI) contribute to vasoconstriction, which elevates the severity of the myocardial infarction. This study aims to investigate the role of cumulative ET-1 and ET-3 levels on the major adverse cardiac events (MACE) 1 year after AMI hospitalization. This retrospective cohort study included patients with ST-elevation acute myocardial infarction (STEMI). Baseline data were collected, including sociodemographic characteristics, clinical data, and serum ET-1 and ET-3 levels, measured with ELISA assay. Follow-up was performed 1 year after hospital discharge to identify MACE. A multivariate logistic regression was performed to describe predictors of 1-year MACE. A total of 81 subjects were enrolled and followed up. Subjects were divided into two groups based on their cumulative ET-1 and ET-3 levels, using a rounded cut-off point of 17.0 ng/mL, produced by the ROC curve for MACE. At 1 year MACE occurred in 24 (29.3%) subjects. A multivariate analysis demonstrated that a cumulative ET-1 and ET-3 level >17.0 ng/mL was independently associated with 1-year MACE (aOR = 5.34, 95% CI: 1.36-21.07,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.